Next Article in Journal
“Add More Arrows to Your Quiver”: The Role of Adding Another Chemotherapy Drug to Fluoropyrimidine and Long Term Radiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis
Previous Article in Journal
A Pilot Case Series on the Use of a Large Mushroom-Shaped Corneal Graft for the Surgical Management of Post-Penetrating Keratoplasty Ectasia and Endothelial Failure
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 14
Issue 2
10.3390/jcm14020341
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Study of Dizziness or Vertigo Cases Associated with Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis) in a Vertigo Outpatient Clinic

by
Teru Kamogashira
*,
Tomoaki Nakada
and
Kaori Kanaya
Department of Otolaryngology, Japan Community Healthcare Organization Tokyo Yamate Medical Center, Hyakunin-cho 3-22-1, Shinjuku-ku 169-0073, Tokyo, Japan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(2), 341; https://doi.org/10.3390/jcm14020341
Submission received: 5 December 2024 / Revised: 31 December 2024 / Accepted: 6 January 2025 / Published: 8 January 2025
(This article belongs to the Section Otolaryngology)
Versions Notes

Abstract

:
Background/Objectives: Dizziness and vertigo are reported in about half of patients with inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). Orthostatic dysregulation (OD) is recognized as one of the comorbidities that causes dizziness or vertigo with IBD. Our hospital is affiliated with the Inflammatory Bowel Disease Center, which specializes in diagnosing and treating IBD, so cases with dizziness or vertigo symptoms associated with IBD are sometimes referred to our department, a type of department which is rare in other facilities. The objective of this study is to evaluate IBD cases with dizziness or vertigo symptoms referred to a vertigo outpatient clinic in terms of vestibular function and OD. Methods: The subjects were 221 patients who were referred to the vertigo outpatient clinic of our department from March 2021 to September 2024. Results: Of the 221 patients, 9 cases had CD and 1 case had UC. OD complications were significantly more common in the IBD group than in the non-IBD group, whereas complications of psychogenic vertigo or migraine were not significantly different between groups, and there was no difference in vestibular dysfunction between groups. OD was a complication in all cases using ustekinumab. Conclusions: An orthostatic test will be valuable for diagnosing OD in IBD patients with dizziness or vertigo symptoms.

1. Introduction

Orthostatic dysregulation (OD) is a condition in which the body’s autonomic nervous system is unable to properly regulate blood pressure and heart rate when changing positions, such as standing up from a lying position [1]. This results in symptoms such as dizziness, lightheadedness, fainting, palpitations, and sometimes nausea. OD is one of the important diseases in otorhinolaryngology clinical practice for vertigo symptoms [2]. Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are primarily gastrointestinal disorders characterized by chronic inflammation. IBD is associated with many extraintestinal manifestations that can affect various organ systems, including arthropathies, skin lesions, anemia, osteopenia, osteoporosis, glomerulonephritis, bronchitis, thromboembolisms, pancreatitis, liver diseases, ocular diseases, and neuropathies [3]. Several organ disorders can cause symptoms of dizziness or vertigo, which are observed in nearly half of patients with IBD [4]. OD associated with autonomic nerve dysfunction (neuropathy) is recognized as one of the comorbidities of IBD [4,5]. The prevalence of OD varies across different populations and age groups [6,7]. The prevalences of orthostatic hypotension, orthostatic hypertension, and orthostatic dizziness in a population-based study were 15.9, 1.1, and 4.8%, respectively [8]. OD has also been reported to be associated with autoimmune diseases [9], and a similar mechanism is expected for IBD, which is considered an autoimmune disease. Our hospital is affiliated with the Inflammatory Bowel Disease Center, which specializes in diagnosing and treating IBD; 24,909 outpatients in cumulative total number, 9156 inpatients, and 362 new patients were treated in 2023, which are especially high numbers compared to other hospitals. Therefore, cases with dizziness or vertigo symptoms associated with IBD are sometimes referred to our department, which is rare in other facilities. The objective of this study is to evaluate IBD cases with dizziness or vertigo symptoms referred to a vertigo outpatient clinic in terms of vestibular function and OD.

2. Materials and Methods

This was a retrospective study conducted at a single institution. Patients referred to the vertigo outpatient clinic, Department of Otolaryngology at Japan Community Healthcare Organization (JCHO) Tokyo Yamate Medical Center from March 2021 to September 2024 were included in this study. Data on prescription histories, scores of questionnaires regarding psychological symptoms, caloric testing results, and vestibular evoked myogenic potential (VEMP) results were collected. Questionnaires included Dizziness Handicap Inventory (DHI) [10], Hospital Anxiety and Depression Scale (HADS) [11], Self-rating Depression Scale (SDS) (age less than 65) [12] or Geriatric Depression Scale (GDS) (age 65 or over) [13,14], POUNDing (Pulsating, duration of 4–72 h, Unilateral, Nausea, Disabling) [15], Migraine Disability Assessment (MIDAS) [16], and 4-item migraine screener (headache exacerbation in daily performance, nausea, light-sensitivity, and hypersensitivity to odors) [17]. Migraine was diagnosed according to the diagnostic criteria [18].
When OD was suspected based on symptoms, an orthostatic test (Schellong test) [19,20] was performed to diagnose OD. In the Schellong test, blood pressure and pulse were measured immediately after 10 min of supine rest, immediately after rapid standing, and after 10 min of standing. Positive results were defined as a decrease in systolic blood pressure of 21 mmHg or more, a narrowing of pulse pressure of 16 mmHg or more, or an increase in pulse rate of 21 or more [21].
Caloric testing was performed in a darkened room by irrigating the external auditory canal with 20 mL saline solution (4 °C) for 10 s. Caloric nystagmus was recorded using the electronystagmography system (ENG NY-50, RION Co., Ltd., Tokyo, Japan), and CP% was calculated from the maximum slow phase velocity of nystagmus using Jongkees’ formula [22]. An abnormal caloric response was defined by either of the following criteria: (1) left or right canal paresis (CP); CP percentage ≥ 20% [23]; or (2) both side CP; maximum slow phase eye velocity < 10 degree/s [24].
The cervical vestibular evoked myogenic potential (cVEMP) and ocular VEMP (oVEMP) were recorded with the electromyography system (MEB-9404, Nihon Kohden Corporation, Tokyo, Japan) using a tone burst stimulus of 500 Hz at 125 dBpeSPL (rise, 1 ms; plateau, 2 ms; and fall, 1 ms) and a tone burst of 1 kHz at 125 dBpeSPL (rise, 1 ms; plateau, 2 ms; and fall, 1 ms). In cVEMP testing, electromyographic (EMG) activity was recorded from a surface electrode placed on the upper half of each sternocleidomastoid muscle (SCM), with a reference electrode on the side of the upper sternum and a ground electrode on the chin. During the recording, in the supine position, subjects were instructed to raise their heads from the pillow to contract the SCM. The EMG signal from the stimulated side was amplified and bandpass-filtered (20–2000 Hz). The stimulation rate was 5.1 Hz, and the analysis time was 100 ms. Responses to 20 stimuli were averaged three times [25]. In oVEMP testing, subjects lay supine on a bed, with their head supported by a pillow and with surface EMG electrodes placed on the skin 1 cm below (active) and 3 cm below (indifferent) the center of each lower eyelid. The ground electrode was placed on the chin. During testing, the subject looked up approximately 30 degrees above straight ahead and maintained their focus on a small dot approximately 1 m from their eyes. The signals were amplified by a differential amplifier (bandwidth: 0.5–500 Hz). Responses to 20 stimuli were averaged three times [25]. An abnormal VEMP response was defined by the following criteria: asymmetry ratio (AR) percentage ≥ 33% or no response in both ears.
We used a force plate (Gravicorder GW-31, Anima Co., Ltd., Tokyo, Japan; sampling frequency: 20 Hz) with/without a foam rubber layer on the posture platform for evaluating postural sway, recording the sway path of the center of pressure (COP). The foam rubber material was made of natural rubber, with a tensile strength of 2.1 Kgf/cm2, an elongation stretch percentage of 110%, a density of 0.06 g/cm3, and a thickness of 3.5 cm. Two-legged standing tasks were performed with both arms at the subject’s side under the four conditions: eyes open or eyes closed, with or without the foam rubber. The position of the distal ends of the big toes were 45 degrees apart with the heels of both feet close to each other. The recording time was 60 s or until the subject required assistance to prevent falling. In the eyes-open condition, the subjects were instructed to look at a small red circle 2 m away from where they were standing in a quiet, well-lit room. We measured the mean velocity of movement of the COP for 60 s, which was termed “the velocity”, and the trace by the movement of the COP, which was termed “the total length”.
Excel Microsoft 365 Apps for enterprise (version 2410, Microsoft, Redmond, WA, USA) was used for processing data. Statistical analyses were performed using R version 4.4.2 software (R Core Team; R Foundation for Statistical Computing, Vienna, Austria, 2024) [26] with tableone package version 0.13.2. Data are expressed as mean ± standard deviation. Welch’s t-test and Fisher’s exact test were applied to compare the data between the two groups after confirming the Kolmogorov–Smirnov normality test (p > 0.05). p < 0.05 was considered statistically significant. Multivariate logistic regression analysis was applied to evaluate the association between IBD and OD. Multivariate regression analysis was applied to evaluate the association between postural sway parameters and OD. The statistical power requirements analysis with the group ratios of 0.5 and 0.1, α-error (Type I error rate) of 0.05, 1-β error (Type II error rate) of 0.8, and the sample size ratio of 20 was 10 and 197, which meet the requirements in this study.
This study and the consent procedure were reviewed and approved by the Research Ethics Committee of JCHO Tokyo Yamate Medical Center, approval number J-145. The information for this study was disclosed, and the participants could choose to opt out. An opt-out informed consent protocol was utilized to collect participant data for research purposes.

3. Results

Of the 221 patients, 9 cases had CD and 1 case had UC. Case characteristics, results of questionnaires, force plate, and vestibular examinations are shown in Table 1. The age was significantly younger in the IBD group than in the non-IBD group, which reflects the age of onset of IBD. There were significantly more males in the IBD group than in the non-IBD group, reflecting that UC is not gender-specific, but that CD is more common in males. OD complications were significantly more common in the IBD group than in the non-IBD group. Complications of psychogenic vertigo tended to be more common in IBD patients than in non-IBD patients, but the difference was not significant. Migraine complications were not significantly different between IBD and non-IBD groups. Results of questionnaires’ scores tended to be higher for the IBD group than for the non-IBD group, but the differences were not significant. There was no difference in vestibular dysfunction between the IBD group and the non-IBD group. Postural sway evaluated with a force plate showed significant normal values in the IBD group compared to the non-IBD group.
Because the IBD group was significantly more male and younger, a multivariate analysis was performed (Table 2), which showed a significant impact on OD complications in IBD, even after accounting for age and gender.
The multivariate analyses of postural sway parameters regarding OD concerning sex, age, and IBD are shown in Table 3. Sex significantly affected total length (eyes opened) and total length (eyes closed), with more normal values in women. Age significantly affected Romberg rate (velocity, rubber), total length (eyes opened), and total length (eyes closed), with more normal values at younger ages (excluding Romberg rate). The prevalence of IBD significantly affected Romberg rate (velocity, rubber) and total length (eyes closed), with more normal values in IBD cases.
A list of cases with IBD referred to the otolaryngology department is presented in Table 4 and Appendix A. All CD patients had a history of abdominal surgery associated with CD. OD complications were equally prevalent in males and females. Females had more migraine complications than males. This suggests the possibility of gender differences in OD, migraine, and symptom severity. In the Schellong test, pulse rate difference or pulse pressure difference was positive in 2 or 3 cases, respectively, but positive systolic blood pressure reduction was not observed in any cases. There were a few cases that did not meet the criteria threshold but were close to it. No specific medications were prescribed for OD. Prescriptions for OD included antihypotensive drugs (amezinium and midodrine), Kampo (Japanese herbal medicine) (Hangebyakujutsu temmato and Ryokeijutukanto), and diphenidol. There were three cases using ustekinumab, all of which were complicated by OD. Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), was prescribed in 8 cases and was not associated with OD complications.
Laboratory test results of patients with IBD are shown in Table 5. Some laboratory test items were not performed in some cases. Nutritional status (total protein, albumin, and vitamin B12), liver function (aspartate transferase (AST), alanine transaminase (ALT), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (gGTP), total bilirubin (T.Bil), and direct bilirubin (D.Bil)), inflammation (c-reactive protein (CRP)), dehydration (blood urea nitrogen (BUN), creatinine (Cre), sodium (Na), potassium (K), and chloride (Cl)), and anemia (hemoglobin (Hb), red blood cell count (RBC), and hematocrit (Hct)) did not differ significantly between patients with and without OD complications. The zinc testing was performed in all cases with OD complications, but not in some cases without OD complications.

4. Discussion

There are multiple possible mechanisms that cause dizziness or vertigo symptoms in Crohn’s disease, which are nutrient malabsorption, side effects of prescription drugs, and chronic inflammation. Severe anemia due to iron deficiency in IBD can also cause dizziness symptoms [27,28,29]. In addition, vitamin B12 or folate deficiency due to malabsorption or poor dietary intake can cause dizziness or fatigue symptoms [30]. Certain medications used to manage IBD, such as steroids or cyclophosphamide, can also cause dizziness as a side effect, likely due to their effects on blood pressure and electrolyte balance [31].
OD is one of the common forms of dysregulation of the autonomic nervous system including the vagus nerve [32,33], and its symptoms are impaired cardiovascular reflexes and orthostatic intolerance, as the body becomes less able to regulate blood pressure and heart rate when changing positions from lying to standing. The chronic systemic inflammatory condition by several cytokines such as tumor necrosis factor-alpha (TNF-α) [34], interleukin-6 (IL-6) [35], interleukin-1-alpha (IL-1α), and interleukin-1-beta (IL-1β) [36,37] is generally observed in IBD, and this condition can damage the autonomic nervous system [38,39] and alter neurological function, affecting blood pressure regulation and heart rate and leading to dizziness or vertigo symptoms due to OD [40]. Past studies have reported autonomic disturbances in IBD, primarily in terms of blood pressure. The systolic blood pressure after tilt was significantly lowered in CD patients compared to controls, both at the first assessment and after seven years [5]. CD patients in remission had preserved cardiac and autonomic function in response to cardiovascular reflex tests and had significantly higher sympathetic-parasympathetic ratio and lower baroreceptor effectiveness and myocardial variables as compared to the healthy controls [41]. UC but not CD patients had greater sympathetic activity than controls in the spectral analysis of heart rate variability to assess cardiac autonomic function [42]. Peripheral sensor-motor neuropathy was relatively frequent in more than one-third of CD patients [4]. Some cytokines that can cross the blood–brain barrier may affect brain regions responsible for balance and proprioception through neuroinflammation by activating microglia [43,44]. Hypothalamic–pituitary–adrenal (HPA) axis may also involve ANS responses [40]. In addition, recent studies suggest an association between IBD and neurodegenerative conditions [45,46], suggesting the importance of the interaction between chronic inflammation and the nervous system. In this study, OD was significantly more common in IBD than in controls, suggesting the importance of OD in dizziness symptoms in IBD.
There are other possible pathways through which chronic inflammation can cause OD. Endothelial cells, which line the blood vessels, are highly sensitive to inflammatory cytokines. Chronic inflammation leads to endothelial dysfunction, reducing the production of nitric oxide (NO), a key vasodilator. NO deficiency can impair blood vessel dilation, affecting blood flow and exacerbating orthostatic intolerance, resulting in reduced vascular responsiveness to positional changes, contributing to the onset of OD in IBD [47,48]. Anemia and hypovolemia are common in IBD due to chronic gastrointestinal bleeding and malabsorption, which can impair oxygen delivery and reduce blood volume. Reduced blood volume contributes to an inability to maintain blood pressure upon standing, a central feature of OD. This combination of anemia and hypovolemia, along with autonomic dysfunction, exacerbates orthostatic intolerance in IBD.
Vestibular dysfunction, potentially linked to autoimmune inner ear disease (AIED), is also a concern in IBD [49,50,51]. The immune dysregulation in IBD can lead to increased susceptibility to autoimmune reactions affecting the inner ear, infiltration of immune cells, and production of antibodies to inner ear antigens that can disrupt the vestibular system, causing dizziness. Biologics and immunosuppressants for managing IBD may also impact vestibular function or cause neurotoxic side effects [52,53]. In this study, the vestibular function was not significantly worse in IBD patients compared to control patients, suggesting that vestibular dysfunction is rare in IBD.
Postural sway, assessed using a force plate, was significantly more normal in the IBD group than in the non-IBD group, indicating the effect of being younger in the IBD group. In the previous study, poor orthostatic tolerance worsens the postural sway parameters as assessed by a force plate [54] and active exaggerated sway improves cardiovascular and cerebrovascular control [55], which are not consistent with the results of this study. IBD complications significantly affected some postural sway parameters, and the IBD group showed significantly better values than the non-IBD group in a multivariate analysis that took sex and age into account. Because the number of cases was small, future prospective studies should validate these findings in larger multicenter cohorts to analyze the impact of multiple factors, including age. Since postural sway evaluates various factors such as psychogenic and central nervous system factors as well as vestibular function, more parameters can be further analyzed, such as the time-frequency spectrum, maximum entropy method [56], and autocorrelation [57].
Recent studies have reported an association between IBD and migraine [58,59,60,61], but further research is needed on a molecular basis. Diagnosis and treatment of migraine in IBD may also be important in terms of vestibular migraine. In this study, the prevalence of migraine did not differ between IBD and controls, which may have been influenced by various factors such as gender and symptoms.
OD was a complication in all cases using ustekinumab, possibly related to the severity of CD. Ustekinumab, which is usually administered by subcutaneous or intravenous injection, is a monoclonal antibody used to treat various autoimmune diseases [62]. In the United States, ustekinumab was approved for psoriasis in 2009 [63], for psoriatic arthritis in 2013, for CD in 2016, and for UC in 2019 [64]. Ustekinumab acts by targeting interleukin-12 (IL-12) and interleukin-23 (IL-23), proteins involved in inflammatory and immune responses. By inhibiting these proteins, ustekinumab reduces inflammation and improves symptoms of these diseases. Recent trials of ustekinumab showed efficacy in treating moderate to severe CD [65]. The UNITI-1 and UNITI-2 trials were randomized, placebo-controlled, phase 3 induction studies evaluating the efficacy of ustekinumab in patients with moderate to severe CD [66]. The UNITI-1 trial included patients who met the criteria for primary or secondary nonresponse to TNF-α antagonists or had unacceptable side effects; the UNITI-2 trial included patients who failed conventional therapy or experienced unacceptable side effects and both trials showed that ustekinumab effectively induced clinical response and remission. UNITI-1 and UNITI-2 patients participated in the IM-UNITI trial to evaluate the long-term efficacy and safety of ustekinumab [67]. Patients who responded to ustekinumab induction therapy maintained clinical response and remission through week 92, supporting the use of ustekinumab as a durable treatment option for severe CD. Based on these trials, the use of ustekinumab is recommended in the treatment algorithm for severe CD, which may reflect the severity of the disease in the data of this study, suggesting an impact of severity on OD complications.
In contrast, mesalazine was prescribed in 8 cases and was not associated with OD complications. Mesalazine is an anti-inflammatory drug used primarily to treat UC and mild-to-moderate CD [68]. Mesalazine inhibits the inflammation of the lining of the gastrointestinal tract by blocking inflammatory mediators such as cytokines and leukotrienes. Mesalazine is usually administered orally or rectally (suppositories or enemas) depending on the site and severity of inflammation [69]. The efficacy of mesalazine in the treatment of mild-to-moderate active CD was equally as effective as a standard dosage of steroids [70]. One systematic review reported that the role of mesalazine in the induction of remission in active CD and prevention of relapse in quiescent CD is still unclear, and more RCTs are needed [71]. Based on these past studies, the presence or absence of mesalazine use is unlikely to reflect the severity of CD. Ustekinumab was prescribed concurrently with mesalazine in two cases, and it was speculated that mesalazine prescriptions were not discontinued even when CD worsened.
In this study, there were no cases of IBD with prominent liver dysfunction and two cases with mildly elevated AST and ALT. There was no significant association between OD and elevated AST or ALT. Hepatobiliary complications are common in IBD, with 30% of patients presenting with abnormal liver function tests and 5% developing chronic liver disease [72]. In a cross-sectional, case-control study, the prevalence of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis did not differ between the IBD and non-IBD groups [73]. These results suggested that the disease is well controlled by treatments, whereas liver function is unlikely to be related to OD.
In the data of this study, there was no significant association between anemia and OD. Impaired stabilization of orthostatic blood pressure and decreased hemoglobin have been reported in chronic kidney disease [74]. Low iron storage is a potentially pathophysiologic factor in both postural orthostatic tachycardia syndrome (POTS) and neurally mediated syncope (NMS) [75,76], suggesting that anemia may affect OD. It is possible that the IBD cases with anemia did not show a significant difference between those with and without OD because they were receiving regular iron supplementation therapy for their anemia, and the values reflected improvement with the therapy.
OD complications were not significantly associated with the zinc testing results based on the available data. However, zinc testing was performed in all cases with OD, but not in those without OD. It is possible that zinc testing tended to be performed more readily in cases of IBD with severe symptoms compared to cases of IBD with mild symptoms. Zinc deficiency in IBD is associated with the development of disease-related complications, and subsequent normalization of zinc levels is associated with improved outcomes [77]. Among the cases in which zinc testing was performed, zinc supplementation therapy was administered in cases of hypozincemia, suggesting that supplementation might be still inadequate. Improvement of various symptoms of IBD with zinc supplementation has been suggested, but whether additional zinc supplementation improves OD should be explored. The prevalence of zinc deficiency was higher in CD patients than in controls, but serum zinc levels were not significantly different between groups [78]. The hypozincemia seen in CD patients is presumably related to accelerated turnover rather than poor zinc absorption [79], suggesting that other underlying treatments, rather than zinc supplementation therapy, may be effective in improving OD.
In the data of this study, no specific medications were prescribed for OD. No particular treatment is particularly effective, and the method considered best for each case was utilized. Treatment strategies for OD include non-pharmacological approaches and pharmacological treatments using antihypotensive drugs [80,81] or Kampo [82]. Non-pharmacological approaches include physical conditioning, hydration with a salt diet, wearing compression garments, and physical counter-maneuvers [83]. Although midodrine has been reported to be effective in previous studies [84,85], a systematic review and meta-analysis of clinical trials have reported a low quality of evidence [81]. Treatment difficulties are speculated, and further new drugs are expected.
Few previous reports have assessed vestibular function in detail in IBD, and this study provides new insights into vestibular function in IBD; however, there are several limitations in this study. Firstly, this was a retrospective study conducted at a single institution. Secondly, the number of cases was too small to analyze differences in symptoms and functions by sex and prescriptions including biologic drugs and immunosuppressants. The risk of bias is high due to the nature of the study, and this study is not complete and should be understood as a preliminary study. Future prospective studies should validate these findings in larger multicenter cohorts. Furthermore, while IBD patients had blood test results for easily deficient items such as Hb, zinc, and vitamin B12, few blood test results were available for the non-IBD group, so comparisons of blood sampling were not possible. Thirdly, nearly half of IBD cases are reported to have dizziness, but most patients do not visit an otolaryngologist, and further research is needed to determine the factors involved in the differences in symptoms. For BPPV, Meniere’s disease, and vestibular neuritis, there may be an autoimmune correlation, but the imbalance has systemic causes, and the help of a neurologist is essential. Additional diagnostic tools such as continuous blood pressure monitoring and neuroimaging could complement the findings. Fourthly, regarding the association of ustekinumab and mesalazine with ODs, each case is assigned to and treated by several physicians, and treatment strategies vary from case to case, thus limiting the ability to make direct comparisons.

5. Conclusions

OD complications were significantly more common in the IBD group than in the non-IBD group. In contrast, migraine complications were not significantly different between groups, and there was no difference in vestibular dysfunction between groups. In previous studies, dizziness or vertigo was reported in about half of the patients with IBD, but it was estimated that the patient was unlikely to see an otorhinolaryngologist. IBD patients experiencing orthostatic symptoms may benefit from therapies that target systemic inflammation, address anemia, and optimize hydration status. Autonomic testing will be valuable for the identification and management of OD in IBD, so autonomic testing should be performed regularly in IBD patients with dizziness or dizziness. The importance of multidisciplinary management of IBD patients, especially in collaboration with otolaryngologists and neurologists, is suggested.

Author Contributions

Conceptualization, T.K.; methodology, T.K.; software, T.K.; validation, T.K.; formal analysis, T.K.; investigation, T.K. and K.K.; resources, T.K.; data curation, T.K.; writing—original draft preparation, T.K.; writing—review and editing, T.N. and K.K.; visualization, T.K.; supervision, K.K.; project administration, K.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study and the consent procedure were reviewed and approved by the Research Ethics Committee of JCHO Tokyo Yamate Medical Center, approval number J-145, 21 June 2022.

Informed Consent Statement

The information for this study was disclosed, and the participants could choose to opt-out. An opt-out informed consent protocol was utilized to collect participant data for research purposes.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author, upon reasonable request with the permission of the research ethics committee.

Acknowledgments

We thank Toshiko Nishi and Rie Kawamata for their technical assistance.

Conflicts of Interest

The authors declare no conflicts of interest.

Appendix A

Table A1. Test results patients with IBD referred to the otolaryngology department.
Table A1. Test results patients with IBD referred to the otolaryngology department.
#Schellong TestPulse
Pressure		Systolic
Diff.		Pulse
Rate Diff.		Pulse
Pressure Diff.
SDPS0D0P0S10D10P10
11348953127976413095634530357411101510
2
3
4109625510868741057169474034141914713
594695610777831028068253022−13−827 *12−53
61026980907594987998331519124141818 *14
71469186137981061429810155394494201516 *11
813484711238585126968750383011814161220 *
91067062106798110883723627250−21910911
109758768555110866098393026121134 *22 *913
#DHIHADSSDSPOUNDingMigraneMIDASRomberg RateRubber RatioTotal LengthCaloric Testing
ADScreener(Velocity, Rubber)(Eyes Closed, Velocity)(Eyes Opened) [cm](Eyes Closed) [cm]L (degree/s)R (degree/s)CP%
11245350011.631.4585.9597.6736.54814
25639390011.291.6174.0384.7113.51711
3285737 1.531.4466.7477.39142222
4 1.911.1147.1153.3620237
5161010480011.291.82100.03106.7911138
664139480011.681.2856.0168.8726.5295
7307444 1.81.0398.84107.6816.52112
81410845 29336
9641817532121.521.9368.8575.698.510.511
10441211473141.61.887.52141.7927.516.525
#cVEMP Left 500 HzcVEMP Left 1 kHzcVEMP Right 500 HzcVEMP Right 1 kHz
n13p23AmplitudeArean13p23AmplitudeArean13p23AmplitudeArean13p23AmplitudeArea
(ms)(ms)(µV)(µVms)(ms)(ms)(µV)(µVms)(ms)(ms)(µV)(µVms)(ms)(ms)(µV)(µVms)
112.21818324091419.718526051318.43133789 02938
210.920.8200195711.820.391.819261318.3111182612.620.21701787
31421.4212337912.520.92693670 02690 02591
411.620.121024191218198215012.719.586.8153612.918.31341756
513.220260330712.622.5348412512.117.6192325712.818.82802818
6 0391713.218.52463727 0440312.816.82334634
714.122429393713.420.9544409713.322446439712.620.13674195
817.622.8127242810.413.81102361 01473 1458
915.324.2236302614.422.9242385214.523.1269371014.723.11874186
1012.720.6473413513.921.14225508 05364 05278
#oVEMP Left 500 HzoVEMP Left 1 kHzoVEMP Right 500 HzoVEMP Right 1 kHzVEMP AR
n1p1base-n1n1-p1Arean1p1base-n1n1-p1Arean1p1base-n1n1-p1Arean1p1base-n1n1-p1AreacVEMPoVEMP
(ms)(ms)amp. (µV)amp. (µV)(µVms)(ms)(ms)amp. (µV)amp. (µV)(µVms)(ms)(ms)amp. (µV)amp. (µV)(µVms)(ms)(ms)amp. (µV)amp. (µV)(µVms)500 Hz1 kHz500 Hz1 kHz
110.412.31.212.088.3810.713.50.383.118.610.515.61.34.377.97 007.974.3100.0 37.6100.0
210.215.67.2812.83.69915.16.9711.24.2410.3162.33.535.269.0515.62.564.553.2725.5 33.267.5 31.0
311.114.90.931.434.5810.914.21.213.857.3410.715.52.854.249.82 005.32100.0 100.0 16.2100.0
410.2145.714.715.69.0511.912.317.712.510.113.511.414.7159.2512.38.5616.317.521.0 9.4 2.120.4
510.815.93.116.956.241015.51.74.539.0710.816.62.914.36.8610.614.416.436.9714.2 8.228.0 29.8
6 0025 0039.9 0017.3 0015.1NR13.6 NRNR
710.816.84.7210.310.89.816.17.6315.810.710.916.84.058.737.139.913.55.389.9511.13.6 20.6 12.424.9
811.313.82.233.697.212.516.74.484.2612.3 009.25 008.87100.0 100.0 100.0 100.0
9 008.96 0016.7 004.77 006.73.7 16.8 NRNR
109.912.61.914.0810.29.2120.993.086.15 006.74 005.54100.0 100.0 100.0 100.0
#: case number, S: systolic pressure, D: diastolic pressure, P: pulse rate, S/D/P(without numbers): blood pressure in the supine position, S0/D0/P0: blood pressure immediately after standing up, S10/D10/P10: blood pressure 10 min after standing up, *: positive for Schellong test, diff.: difference, amp.: amplitude, AR: asymmetry ratio, NR: no response in both ears.

References

  1. Streeten, D.H.P.; Anderson, G.H. Delayed Orthostatic Intolerance. Arch. Intern. Med. 1992, 152, 1066–1072. [Google Scholar] [CrossRef] [PubMed]
  2. Aoki, M.; Sakaida, Y.; Hayashi, H.; Yamada, N.; Mizuta, K.; Ito, Y. The orthostatic dysregulation of blood pressure in dizzy patients. J. Vestib. Res. 2008, 18, 223–229. [Google Scholar] [CrossRef] [PubMed]
  3. Ott, C.; Scholmerich, J. Extraintestinal manifestations and complications in IBD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 585–595. [Google Scholar] [CrossRef] [PubMed]
  4. Wasserbauer, M.; Mala, S.; Stechova, K.; Hlava, S.; Cernikova, P.; Stovicek, J.; Drabek, J.; Broz, J.; Pichlerova, D.; Kucerova, B.; et al. Dysfunction of peripheral somatic and autonomic nervous system in patients with severe forms of Crohn’s disease on biological therapy with TNFα inhibitors—A single center study. PLoS ONE 2023, 18, e0294441. [Google Scholar] [CrossRef]
  5. Ohlsson, B.; Sundkvist, G.; Lindgren, S. Subclinical sympathetic neuropathy appears early in the course of Crohn’s disease. BMC Gastroenterol. 2007, 7, 33. [Google Scholar] [CrossRef]
  6. Rutan, G.H.; Hermanson, B.; Bild, D.E.; Kittner, S.J.; LaBaw, F.; Tell, G.S. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992, 19, 508–519. [Google Scholar] [CrossRef]
  7. Freeman, R.; Wieling, W.; Axelrod, F.B.; Benditt, D.G.; Benarroch, E.; Biaggioni, I.; Cheshire, W.P.; Chelimsky, T.; Cortelli, P.; Gibbons, C.H.; et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin. Auton. Res. 2011, 21, 69–72. [Google Scholar] [CrossRef]
  8. Wu, J.-S.; Yang, Y.-C.; Lu, F.-H.; Wu, C.-H.; Chang, C.-J. Population-based study on the prevalence and correlates of orthostatic hypotension/hypertension and orthostatic dizziness. Hypertens. Res. 2008, 31, 897–904. [Google Scholar] [CrossRef]
  9. Pena, C.; Moustafa, A.; Mohamed, A.-R.; Grubb, B. Autoimmunity in Syndromes of Orthostatic Intolerance: An Updated Review. J. Pers. Med. 2024, 14, 435. [Google Scholar] [CrossRef]
  10. Jacobson, G.P.; Newman, C.W. The Development of the Dizziness Handicap Inventory. Arch. Otolaryngol. Neck Surg. 1990, 116, 424–427. [Google Scholar] [CrossRef]
  11. Zigmond, A.S.; Snaith, R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 1983, 67, 361–370. [Google Scholar] [CrossRef] [PubMed]
  12. Zung, W.W.K. A Self-Rating Depression Scale. Arch. Gen. Psychiatry 1965, 12, 63–70. [Google Scholar] [CrossRef] [PubMed]
  13. Yesavage, J.A.; Brink, T.L.; Rose, T.L.; Lum, O.; Huang, V.; Adey, M.; Leirer, V.O. Development and validation of a geriatric depression screening scale: A preliminary report. J. Psychiatr. Res. 1982, 17, 37–49. [Google Scholar] [CrossRef] [PubMed]
  14. Sheikh, J.I.; Yesavage, J.A. 9/geriatric depression scale (Gds) recent evidence and development of a shorter version. Clin. Gerontol. 1986, 5, 165–173. [Google Scholar] [CrossRef]
  15. Detsky, M.E.; McDonald, D.R.; Baerlocher, M.O.; Tomlinson, G.A.; McCrory, D.C.; Booth, C.M. Does this patient with headache have a migraine or need neuroimaging? JAMA 2006, 296, 1274–1283. [Google Scholar] [CrossRef]
  16. Stewart, W.F.; Lipton, R.B.; Dowson, A.J.; Sawyer, J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001, 56, S20–S28. [Google Scholar] [CrossRef]
  17. Takeshima, T.; Sakai, F.; Suzuki, N.; Shimizu, T.; Igarashi, H.; Araki, N.; Manaka, S.; Nakashima, K.; Hashimoto, Y.; Iwata, M.; et al. A simple migraine screening instrument; Validation study in Japan. Jpn. J. Headache 2015, 42, 134–143. [Google Scholar]
  18. Olesen, J. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders. Cephalalgia 2018, 38, 1–211. [Google Scholar]
  19. Schellong, F.; Lüderitz, B. Regulationsprüfung Des Kreislaufs Funktionelle Differentialdiagnose von Herz- und Gefässstörungen; Steinkopff: Berlin, Germany, 1954. [Google Scholar]
  20. Fanciulli, A.; Campese, N.; Wenning, G.K. The Schellong test: Detecting orthostatic blood pressure and heart rate changes in German-speaking countries. Clin. Auton. Res. 2019, 29, 363–366. [Google Scholar] [CrossRef]
  21. Japan Society of Neurovegetative Research Head-up tilt test and Orthostatic test. In Autonomic Nerve Function Test; Bunkodo: Tokyo, Japan, 2015.
  22. Schmäl, F.; Lübben, B.; Weiberg, K.; Stoll, W. The minimal ice water caloric test compared with established vestibular caloric test procedures. J. Vestib. Res. Equilib. Orientat. 2005, 15, 215–224. [Google Scholar] [CrossRef]
  23. Iwasaki, S.; Takai, Y.; Ozeki, H.; Ito, K.; Karino, S.; Murofushi, T. Extent of lesions in idiopathic sudden hearing loss with vertigo: Study using click and galvanic vestibular evoked myogenic potentials. Arch. Otolaryngol.—Head Neck Surg. 2005, 131, 857–862. [Google Scholar] [CrossRef] [PubMed]
  24. Fujimoto, C.; Murofushi, T.; Chihara, Y.; Suzuki, M.; Yamasoba, T.; Iwasaki, S. Novel subtype of idiopathic bilateral vestibulopathy: Bilateral absence of vestibular evoked myogenic potentials in the presence of normal caloric responses. J. Neurol. 2009, 256, 1488–1492. [Google Scholar] [CrossRef] [PubMed]
  25. Fujimoto, C.; Egami, N.; Kinoshita, M.; Sugasawa, K.; Yamasoba, T.; Iwasaki, S. Involvement of vestibular organs in idiopathic sudden hearing loss with vertigo: An analysis using oVEMP and cVEMP testing. Clin. Neurophysiol. 2015, 126, 1033–1038. [Google Scholar] [CrossRef]
  26. R Core Team. R Core Team R: A Language and Environment for Statistical Computing; R Core Team: Vienna, Austria, 2024. [Google Scholar]
  27. Stein, J.; Dignass, A.U. Management of iron deficiency anemia in inflammatory bowel disease—A practical approach. Ann. Gastroenterol. 2013, 26, 104–113. [Google Scholar]
  28. Mahadea, D.; Adamczewska, E.; Ratajczak, A.E.; Rychter, A.M.; Zawada, A.; Eder, P.; Dobrowolska, A.; Krela-Kaźmierczak, I. Iron deficiency anemia in inflammatory bowel diseases—A narrative review. Nutrients 2021, 13, 4008. [Google Scholar] [CrossRef]
  29. Abomhya, A.; Tai, W.; Ayaz, S.; Khan, F.; Saadedeen, W.; Ajala, O.; Mohamed, R. Iron Deficiency Anemia: An Overlooked Complication of Crohn’s Disease. J. Hematol. 2022, 11, 55–61. [Google Scholar] [CrossRef]
  30. Włodarczyk, M.; Makaro, A.; Prusisz, M.; Włodarczyk, J.; Nowocień, M.; Maryńczak, K.; Fichna, J.; Dziki, Ł. The Role of Chronic Fatigue in Patients with Crohn’s Disease. Life 2023, 13, 1692. [Google Scholar] [CrossRef]
  31. Bär, F.; Krause, T.; Stallmach, A.; Teich, N.; Maaser, C.; Maul, J.; Helwig, U.; Fellermann, K.; Büning, J. Cyclophosphamide Pulse Therapy in Severe Refractory Crohn’s Disease: A Retrospective Multicenter Case Series. Inflamm. Intest. Dis. 2018, 2, 139–146. [Google Scholar] [CrossRef]
  32. Ringer, M.; Lappin, S.L. Orthostatic Hypotension; StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
  33. Zhao, S.; Tran, V.H. Postural Orthostatic Tachycardia Syndrome; StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
  34. Murch, S.H.; Braegger, C.P.; Walker-Smith, J.A.; MacDonald, T.T. Location of tumour necrosis factor a by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993, 34, 1705–1709. [Google Scholar] [CrossRef]
  35. Mudter, J.; Neurath, M.F. IL-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance. Inflamm. Bowel Dis. 2007, 13, 1016–1023. [Google Scholar] [CrossRef]
  36. Elsässer-Beile, U.; von Kleist, S.; Gerlach, S.; Gallati, H.; Mönting, J.S. Cytokine production in whole blood cell cultures of patients with crohn’s disease and ulcerative colitis. J. Clin. Lab. Anal. 1994, 8, 447–451. [Google Scholar] [CrossRef] [PubMed]
  37. Anka Idrissi, D.; Senhaji, N.; Aouiss, A.; Khalki, L.; Tijani, Y.; Zaid, N.; Marhoume, F.Z.; Naya, A.; Oudghiri, M.; Kabine, M.; et al. IL-1 and CD40/CD40L platelet complex: Elements of induction of Crohn’s disease and new therapeutic targets. Arch. Pharm. Res. 2021, 44, 117–132. [Google Scholar] [CrossRef] [PubMed]
  38. Dvorak, A.M.; Silen, W. Differentiation between Crohn’s disease and other inflammatory conditions by electron microscopy. Ann. Surg. 1985, 201, 53–63. [Google Scholar] [CrossRef]
  39. Geboes, K.; Collins, S. Structural abnormalities of the nervous system in Crohn’s disease and ulcerative colitis. Neurogastroenterol. Motil. 1998, 10, 189–202. [Google Scholar] [CrossRef]
  40. Straub, R.H.; Herfarth, H.; Falk, W.; Andus, T.; Schölmerich, J. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease? J. Neuroimmunol. 2002, 126, 116–125. [Google Scholar] [CrossRef]
  41. Zawadka-Kunikowska, M.; Słomko, J.; Kłopocka, M.; Liebert, A.; Tafil-Klawe, M.; Klawe, J.J.; Newton, J.L.; Zalewski, P. Cardiac and autonomic function in patients with Crohn’s disease during remission. Adv. Med. Sci. 2018, 63, 334–340. [Google Scholar] [CrossRef]
  42. Ganguli, S.C.; Kamath, M.V.; Redmond, K.; Chen, Y.; Irvine, E.J.; Collins, S.M.; Tougas, G. A comparison of autonomic function in patients with inflammatory bowel disease and in healthy controls. Neurogastroenterol. Motil. 2007, 19, 961–967. [Google Scholar] [CrossRef]
  43. Banks, W.A.; Kastin, A.J.; Broadwell, R.D. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995, 2, 241–248. [Google Scholar] [CrossRef]
  44. Banks, W. Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology. Curr. Pharm. Des. 2005, 11, 973–984. [Google Scholar] [CrossRef]
  45. Kim, J.S.; Chen, M.H.; Wang, H.E.; Lu, C.L.; Wang, Y.P.; Zhang, B. Inflammatory Bowel Disease and Neurodegenerative Diseases. Gut Liver 2023, 17, 495–504. [Google Scholar] [CrossRef]
  46. Puckett, Y.; Gabbar, A.; Bokhari, A.A. Prednisone; StatPearls Publishing: Treasure Island, FL, USA, 2024; ISBN 9780080552323. [Google Scholar]
  47. Roifman, I.; Sun, Y.C.; Fedwick, J.P.; Panaccione, R.; Buret, A.G.; Liu, H.; Rostom, A.; Anderson, T.J.; Beck, P.L. Evidence of Endothelial Dysfunction in Patients With Inflammatory Bowel Disease. Clin. Gastroenterol. Hepatol. 2009, 7, 175–182. [Google Scholar] [CrossRef] [PubMed]
  48. Gravina, A.G.; Dallio, M.; Masarone, M.; Rosato, V.; Aglitti, A.; Persico, M.; Loguercio, C.; Federico, A. Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets. Oxid. Med. Cell. Longev. 2018, 2018, 2568569. [Google Scholar] [CrossRef] [PubMed]
  49. Dettmer, M.; Hegemann, I.; Hegemann, S.C.A. Extraintestinal Crohn’s disease mimicking autoimmune inner ear disease: A histopathological approach. Audiol. Neurotol. 2010, 16, 36–40. [Google Scholar] [CrossRef]
  50. Vavricka, S.R.; Greuter, T.; Scharl, M.; Mantzaris, G.; Shitrit, A.B.; Filip, R.; Karmiris, K.; Thoeringer, C.K.; Boldys, H.; Wewer, A.V.; et al. Cogan’s Syndrome in Patients with Inflammatory Bowel Disease—A Case Series. J. Crohns. Colitis 2015, 9, 886–890. [Google Scholar] [CrossRef]
  51. Fousekis, F.S.; Saridi, M.; Albani, E.; Daniel, F.; Katsanos, K.H.; Kastanioudakis, I.G.; Christodoulou, D.K. Ear Involvement in Inflammatory Bowel Disease: A Review of the Literature. J. Clin. Med. Res. 2018, 10, 609–614. [Google Scholar] [CrossRef]
  52. Wijdicks, E.F.M. Neurotoxicity of immunosuppressive drugs. Liver Transplant. 2001, 7, 937–942. [Google Scholar] [CrossRef]
  53. Anghel, D.; Tanasescu, R.; Campeanu, A.; Lupescu, I.; Podda, G.; Bajenaru, O. Neurotoxicity of immunosuppressive therapies in organ transplantation. Maedica 2013, 8, 170–175. [Google Scholar]
  54. Claydon, V.E.; Hainsworth, R. Postural sway in patients with syncope and poor orthostatic tolerance. Heart 2006, 92, 1688–1689. [Google Scholar] [CrossRef]
  55. Williams, E.L.; Hockin, B.C.D.; Heeney, N.D.; Elabd, K.; Chong, H.; Blaber, A.P.; Robinovitch, S.N.; Parsons, I.T.; Claydon, V.E. Exaggerated postural sway improves orthostatic cardiovascular and cerebrovascular control. Front. Cardiovasc. Med. 2023, 10, 1040036. [Google Scholar] [CrossRef]
  56. Funato, T.; Aoi, S.; Tomita, N.; Tsuchiya, K. Smooth enlargement of human standing sway by instability due to weak reaction floor and noise. R. Soc. Open Sci. 2016, 3, 150570. [Google Scholar] [CrossRef]
  57. Nagai, K.; Aoyama, T.; Yamada, M.; Izeki, M.; Fujibayashi, S.; Takemoto, M.; Nishiguchi, S.; Tsuboyama, T.; Neo, M. Quantification of changes in gait characteristics associated with intermittent claudication in patients with lumbar spinal stenosis. J. Spinal Disord. Tech. 2014, 27, E136–E142. [Google Scholar] [CrossRef] [PubMed]
  58. Ford, S.; Finkel, A.G.; Isaacs, K.L. Migraine in patients with inflammatory bowel disorders. J. Clin. Gastroenterol. 2009, 43, 499. [Google Scholar] [CrossRef] [PubMed]
  59. Dimitrova, A.K.; Ungaro, R.C.; Lebwohl, B.; Lewis, S.K.; Tennyson, C.A.; Green, M.W.; Babyatsky, M.W.; Green, P.H. Prevalence of migraine in patients with celiac disease and inflammatory bowel disease. Headache 2013, 53, 344–355. [Google Scholar] [CrossRef] [PubMed]
  60. Moisset, X.; Bommelaer, G.; Boube, M.; Ouchchane, L.; Goutte, M.; Dapoigny, M.; Dallel, R.; Guttmann, A.; Clavelou, P.; Buisson, A. Migraine prevalence in inflammatory bowel disease patients: A tertiary-care centre cross-sectional study. Eur. J. Pain 2017, 21, 1550–1560. [Google Scholar] [CrossRef]
  61. Lee, C.H.; Han, K.; Lee, H.J.; Yu, H.; Kim, S.; Choi, K.; Koh, S.J.; Im, J.P.; Kim, J.S. Migraine is associated with the development of adult patients with inflammatory bowel disease: A nationwide, population-based study. Sci. Rep. 2024, 14, 1157. [Google Scholar] [CrossRef]
  62. Krueger, G.G.; Langley, R.G.; Leonardi, C.; Yeilding, N.; Guzzo, C.; Wang, Y.; Dooley, L.T.; Lebwohl, M. A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis. N. Engl. J. Med. 2007, 356, 580–592. [Google Scholar] [CrossRef]
  63. Leonardi, C.L.; Kimball, A.B.; Papp, K.A.; Yeilding, N.; Guzzo, C.; Wang, Y.; Li, S.; Dooley, L.T.; Gordon, K.B. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371, 1665–1674. [Google Scholar] [CrossRef]
  64. Sandborn, W.J.; Feagan, B.G.; Danese, S.; O’Brien, C.D.; Ott, E.; Marano, C.; Baker, T.; Zhou, Y.; Volger, S.; Tikhonov, I.; et al. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflamm. Bowel Dis. 2021, 27, 994–1007. [Google Scholar] [CrossRef]
  65. D’Amico, F.; Peyrin-Biroulet, L.; Danese, S. Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm. J. Crohns. Colitis 2022, 16, ii30–ii41. [Google Scholar] [CrossRef]
  66. Feagan, B.G.; Sandborn, W.J.; Gasink, C.; Jacobstein, D.; Lang, Y.; Friedman, J.R.; Blank, M.A.; Johanns, J.; Gao, L.-L.; Miao, Y.; et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N. Engl. J. Med. 2016, 375, 1946–1960. [Google Scholar] [CrossRef]
  67. Sandborn, W.J.; Rutgeerts, P.; Gasink, C.; Jacobstein, D.; Zou, B.; Johanns, J.; Sands, B.E.; Hanauer, S.B.; Targan, S.; Ghosh, S.; et al. Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment. Pharmacol. Ther. 2018, 48, 65–77. [Google Scholar] [CrossRef] [PubMed]
  68. Böhm, S.K.; Kruis, W. Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clin. Exp. Gastroenterol. 2014, 7, 369–383. [Google Scholar] [CrossRef] [PubMed]
  69. Murphy, W.; Liu, S.; Javadiyan, S.; Vyskocil, E.; Feizi, S.; Callejas, C.; Wormald, P.-J.; Vreugde, S.; Psaltis, A.J. An In Vitro Study Evaluating the Safety of Mesalazine on Human Nasoepithelial Cells. Int. J. Mol. Sci. 2024, 25, 2796. [Google Scholar] [CrossRef] [PubMed]
  70. Prantera, C.; Cottone, M.; Pallone, F.; Annese, V.; Franzè, A.; Cerutti, R.; Bianchi Porro, G. Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: Results of a randomized, multicenter trial. Gastroenterology 1999, 116, 521–526. [Google Scholar] [CrossRef]
  71. Ford, A.C.; Kane, S.V.; Khan, K.J.; Achkar, J.-P.; Talley, N.J.; Marshall, J.K.; Moayyedi, P. Efficacy of 5-aminosalicylates in Crohn’s disease: Systematic review and meta-analysis. Am. J. Gastroenterol. 2011, 106, 617–629. [Google Scholar] [CrossRef]
  72. Gaspar, R.; Branco, C.C.; Macedo, G. Liver manifestations and complications in inflammatory bowel disease: A review. World J. Hepatol. 2021, 13, 1956–1967. [Google Scholar] [CrossRef]
  73. Martínez-Domínguez, S.J.; García-Mateo, S.; Gargallo-Puyuelo, C.J.; Gallego Llera, B.; Refaie, E.; Callau, P.; Mendi, C.; Baptista, P.M.; Hernández Ainsa, M.; Arroyo-Villarino, M.T.; et al. Crohn’s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease. Eur. J. Intern. Med. 2024, 120, 99–106. [Google Scholar] [CrossRef]
  74. Liu, W.; Wang, L.; Huang, X.; He, W.; Song, Z.; Yang, J. Impaired orthostatic blood pressure stabilization and reduced hemoglobin in chronic kidney disease. J. Clin. Hypertens. 2019, 21, 1317–1324. [Google Scholar] [CrossRef]
  75. Jarjour, I.T.; Jarjour, L.K. Low iron storage in children and adolescents with neurally mediated syncope. J. Pediatr. 2008, 153, 40–44. [Google Scholar] [CrossRef]
  76. Jarjour, I.T.; Jarjour, L.K. Low iron storage and mild anemia in postural tachycardia syndrome in adolescents. Clin. Auton. Res. 2013, 23, 175–179. [Google Scholar] [CrossRef]
  77. Siva, S.; Rubin, D.T.; Gulotta, G.; Wroblewski, K.; Pekow, J. Zinc deficiency is associated with poor clinical outcomes in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2017, 23, 152–157. [Google Scholar] [CrossRef] [PubMed]
  78. Soltani, Z.; Rafiei, F.; EBRAHIMi, A.; Rafiei, R. The Prevalence of Zinc Deficiency in Crohn’s Disease Patients. Maedica 2021, 16, 29–33. [Google Scholar] [CrossRef] [PubMed]
  79. Nakamura, T.; Higashi, A.; Takano, S.; Akagi, M.; Matsuda, I. Zinc clearance correlates with clinical severity of Crohn’s disease—A kinetic study. Dig. Dis. Sci. 1988, 33, 1520–1524. [Google Scholar] [CrossRef]
  80. Kita, K.; Hirayama, K. Treatment of neurogenic orthostatic hypotension with amezinium metilsulfate, a new indirect sympathomimetic drug. Neurology 1988, 38, 1095–1099. [Google Scholar] [CrossRef] [PubMed]
  81. Parsaik, A.K.; Singh, B.; Altayar, O.; Mascarenhas, S.S.; Singh, S.K.; Erwin, P.J.; Murad, M.H. Midodrine for orthostatic hypotension: A systematic review and meta-analysis of clinical trials. J. Gen. Intern. Med. 2013, 28, 1496–1503. [Google Scholar] [CrossRef]
  82. Sakata, M.; Egami, H. Successful treatment of orthostatic dysregulation with Japanese (Kampo) herbal medicine ryokeijutsukanto. Explore 2021, 17, 521–524. [Google Scholar] [CrossRef]
  83. Momodu, I.I.; Okafor, C.N. Orthostatic Syncope (Archived); StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
  84. Jankovic, J.; Gilden, J.L.; Hiner, B.C.; Kaufmann, H.; Brown, D.C.; Coghlan, C.H.; Rubin, M.; Fouad-Tarazi, F.M. Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrine. Am. J. Med. 1993, 95, 38–48. [Google Scholar] [CrossRef]
  85. Low, P.A.; Gilden, J.L.; Freeman, R.; Sheng, K.N.; McElligott, M.A. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: A randomized, double-blind multicenter study. JAMA 1997, 277, 1046–1051. [Google Scholar] [CrossRef]
Table 1. Case characteristics and results of examinations.
Table 1. Case characteristics and results of examinations.
non-IBD (n = 211) IBD (n = 10) p Value
Sex [Male] 83 (39.3) 8 (80.0) 0.02 *
Age 62.5 ± 18.8 46.7 ± 12.8 0.01 *
OD 23/211 (11%) 5/10 (50%) <0.01 *
Psychogenic vertigo 98/211 (47%) 7/10 (70%) 0.20
Migraine 36/211 (17%) 2/10 (20%) 0.68
DHI 32.1 ± 21.7 36.4 ± 21.2 0.56
HADS/A 6.9 ± 4.1 9.1 ± 4.9 0.22
HADS/D 6.1 ± 4.0 8.9 ± 3.8 0.06
SDS 42.4 ± 9.8 44.0 ± 5.9 0.48
POUNDing 0.7 ± 1.3 0.8 ± 1.3 0.86
MIDAS 1.4 ± 1.0 1.7–1.2 0.63
Migraine screener [positive] 30/139 (22%) 2/6 (33%) 0.61
Romberg rate (velocity, rubber) 1.8 ± 0.5 1.6 ± 0.2 0.01 *
Rubber ratio (eyes closed, velocity) 1.8 ± 0.8 1.5 ± 0.3 0.04 *
Total length (eyes opened) [cm] 102.1 ± 52.1 76.1 ± 18.4 <0.01 *
Total length (eyes closed) [cm] 145.3 ± 76.6 90.4 ± 26.3 <0.01 *
Caloric testing [abnormal] 106/208 (51%) 2/10 (20%) 0.14
cVEMP 500 Hz [abnormal] 134/205 (65%) 4/10 (40%) 0.17
cVEMP 1 kHz [abnormal] 135/205 (65%) 5/10 (50%) 0.32
oVEMP 500 Hz [abnormal] 167/205 (82%) 6/10 (60%) 0.11
oVEMP 1 kHz [abnormal] 174/205 (85%) 6/10 (60%) 0.06
OD: orthostatic dysregulation; DHI: dizziness handicap inventory; HADS: hospital anxiety and depression scale; SDS: self-rating depression scale; POUNDing: pulsating, duration of 4–72 h, unilateral, nausea, disabling; MIDAS: migraine disability assessment; cVEMP: cervical vestibular evoked myogenic potential; oVEMP: ocular cervical vestibular evoked myogenic potential. *: p < 0.05.
Table 2. Multivariate analysis of the prevalence of OD concerning sex, age, and IBD.
Table 2. Multivariate analysis of the prevalence of OD concerning sex, age, and IBD.
Estimate Std. Error z Value Pr (>|z)
(Intercept) −1.5332 0.70395 −2.178 0.02941 *
Sex 0.2109 0.43231 0.488 0.62565
Age −0.01073 0.01106 −0.97 0.33224
IBD 1.86558 0.70719 2.638 0.00834 **
*: p < 0.05; **: p < 0.01.
Table 3. Multivariate analyses of postural sway concerning sex, age, and IBD.
Table 3. Multivariate analyses of postural sway concerning sex, age, and IBD.
(a) Romberg Rate (Velocity, Rubber)(b) Rubber Ratio (Eyes Closed, Velocity)
EstimateStd. Errort ValuePr (>|t|) EstimateStd. Errort ValuePr (>|t|)
(Intercept)2.10370.138515.1860<2 × 10−16 ***(Intercept)1.76300.21668.14008.05 × 10−14 ***
Sex0.12470.07861.58500.1148Sex0.02440.12300.19800.8430
Age−0.00550.0021−2.61600.0097 **Age0.00010.00330.01900.9850
IBD−0.36560.1795−2.03700.0432 *IBD−0.28820.2806−1.02700.3060
(c) Total Length (Eyes Opened)(d) Total Length (Eyes Closed)
EstimateStd. Errort ValuePr (>|t|) EstimateStd. Errort ValuePr (>|t|)
(Intercept)25.288212.26932.06100.04059 *(Intercept)66.431818.69573.55300.000477 ***
Sex18.82696.86452.74300.00665 **Sex35.334510.51433.36100.000935 ***
Age1.12270.18386.10705.19 × 10−9 ***Age1.05130.28153.73500.000246 ***
IBD−14.832516.7397−0.88600.3767IBD−51.252225.4190−2.01600.045134 *
*: p < 0.05; **: p < 0.01; ***: p < 0.001.
Table 4. Case series of patients with IBD referred to the otolaryngology department.
Table 4. Case series of patients with IBD referred to the otolaryngology department.
#SexAgeIBDDisease PeriodDiagnosis
of IBD (years)
1M49CD24BPPV
2M44CD17BPPV after traffic trauma
3M49CD28Peripheral vestibular dysfunction
4M22CD6Psychogenic vertigo, Delayed endolymphatic hydrops
5M51CD30Psychogenic vertigo, OD
6M60CD27Psychogenic vertigo, OD
7M63UC4Psychogenic vertigo, OD
8M58CD22Psychogenic vertigo, OD, Parkinson’s disease
9F38CD18Psychogenic vertigo, Migraine
10F33CD18Meniere’s disease (probable), Migraine, OD
#Prescriptions Related to IBDPrescriptions Related to Dizziness
1Mesalazine, Budesonide (enema)−
2Mesalazine−
3Mesalazine, Risankizumab−
4Mesalazine, Salazosulfapyridine, Metronidazole, AzathioprineAmezinium, Domperidone, Hangebyakujutsu temmato, Goshuyu, Saireito
5Mesalazine−
6Mesalazine, UstekinumabBetahistine, Ryokeijutukanto
7Salazosulfapyridine, MesalazineBetahistine
8Salazosulfapyridine, UstekinumabMidodrine, Diphenidol, Ryokeijutukanto
9MesalazineHangebyakujutsu temmato, Goshuyu
10UstekinumabValproate, Chlorpheniramine, Acetaminophen, Midodrine, Goshuyu, Tokishakuyakusan
#: case number, M: male, F: female, IBD: inflammatory bowel disease, CD: Crohn’s disease, UC: ulcerative colitis, BPPV: benign paroxysmal positional vertigo.
Table 5. Laboratory test results of patients with IBD referred to the otolaryngology department.
Table 5. Laboratory test results of patients with IBD referred to the otolaryngology department.
#ODDaysTPAlbASTALTLDHALPgGTPT.BilD.BilAmyT-CholHDLLDLBUNCreCRPZnFeVB12NaKClHbRBCHct
1−−337.74.417191648217 0.1 78105 12.347139.8
2−686.33.8376635899 65 121.11 63 1403.710813.544938.4
3−−126.8422261731341150.80.170122 191.020.186211 1434.210914.547644.6
4−2197.24.3212019953381.209098324760.880.1 139410515.852645.1
5+−617.94.1404713510254 1011435456111.030.1751072791393.39814.447941.7
6+−196.93.7221518590 100.80.175 ≤501424.110413.846442.4
7+−107.64.424251447719 68240 160.980.1113 1444.210716.451148.3
8+−1474.3261624753240.50871817197250.970.169112 1403.910113.642440.9
9−−287.23.5171413073250.4 209193718190.490.76456 14141051247539.1
10+07.93.520181287610 105 70.620.189421561383.910611.744437.3
#: case number, Days: days between laboratory test and vestibular test, TP: total protein [g/dL], Alb: albumin [g/dL], AST: aspartate transferase [U/L], ALT: alanine transaminase [U/L], LDH: lactate dehydrogenase [U/L], ALP: alkaline phosphatase [U/L], gGTP: gamma-glutamyl transpeptidase [U/L], T.Bil: total bilirubin [mg/dL], D.Bil: direct bilirubin [mg/dL], Amy: amylase [U/L], T-Chol: total cholesterol [mg/dL], HDL: high-density lipoprotein [mg/dL], LDL: low-density lipoprotein [mg/dL], BUN: blood urea nitrogen [mg/dL], Cre: creatinine [mg/dL], CRP: c-reactive protein [mg/dL], Zn: zinc [µg/dL], Fe: VB12: vitamin B12 [µg/dL], Na: sodium [mEq/L], K: potassium [mEq/L], Cl: chloride [mEq/L], Hb: hemoglobin [g/dL], RBC: red blood cell count [×104/µL], Hct: hematocrit [%].
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kamogashira, T.; Nakada, T.; Kanaya, K. A Study of Dizziness or Vertigo Cases Associated with Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis) in a Vertigo Outpatient Clinic. J. Clin. Med. 2025, 14, 341. https://doi.org/10.3390/jcm14020341

AMA Style

Kamogashira T, Nakada T, Kanaya K. A Study of Dizziness or Vertigo Cases Associated with Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis) in a Vertigo Outpatient Clinic. Journal of Clinical Medicine. 2025; 14(2):341. https://doi.org/10.3390/jcm14020341

Chicago/Turabian Style

Kamogashira, Teru, Tomoaki Nakada, and Kaori Kanaya. 2025. "A Study of Dizziness or Vertigo Cases Associated with Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis) in a Vertigo Outpatient Clinic" Journal of Clinical Medicine 14, no. 2: 341. https://doi.org/10.3390/jcm14020341

APA Style

Kamogashira, T., Nakada, T., & Kanaya, K. (2025). A Study of Dizziness or Vertigo Cases Associated with Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis) in a Vertigo Outpatient Clinic. Journal of Clinical Medicine, 14(2), 341. https://doi.org/10.3390/jcm14020341

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop